Clinical trials for tyrosine kinase (including SRC) inhibitors have shown beneficial outcome for adult patients with Philadelphia chromosome‐positive chronic myeloid leukemia (CML; Cortes et al, 2018) and are being tested in combination with EGFR inhibitors for advanced pancreatic cancer (Cardin et al, 2018) or alone for the treatment of newly diagnosed endometrial cancer (Duska et al, 2019). This evidence concerns the gene SRC and chronic myelogenous leukemia, BCR-ABL1 positive.